TenX Keane Acquisition Announces Extension Of The Deadline For An Initial Business Combination To January 18, 2024

10/18/23 4:03:12 PM ET

Blank Checks

Finance

Get the next $TENK alert in real time by email

TenX Keane Acquisition (the "Company") (NASDAQ:TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from October 18, 2023 to January 18, 2024, the Company has deposited into its trust account (the "Trust Account") an aggregate of $660,000 (the "Extension Fee"), representing $0.10 per public share of the Company. The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the "Sponsor"), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor.

Get the next $TENK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TENK

Date	Price Target	Rating	Analyst

More analyst ratings

$TENK
Press Releases

Fastest customizable press release news feed in the world

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202
8/9/24 7:30:00 AM ET
$CTXR
$TENK
Biotechnology: Pharmaceutical Preparations
Health Care
Blank Checks
Finance
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own
8/5/24 8:00:00 AM ET
$CTXR
$TENK
Biotechnology: Pharmaceutical Preparations
Health Care
Blank Checks
Finance
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane
8/5/24 8:00:00 AM ET
$CTXR
$TENK
Biotechnology: Pharmaceutical Preparations
Health Care
Blank Checks
Finance

TenX Keane Acquisition Announces Extension Of The Deadline For An Initial Business Combination To January 18, 2024

Chat with this insight

Recent Analyst Ratings for
$TENK

$TENK
Press Releases

Fastest customizable press release news feed in the world

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

$TENK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Dutia Suren G

SEC Form 4 filed by Director Holubiak Myron Z

SEC Form 4 filed by Chief Medical Officer Czuczman Myron

$TENK
SEC Filings

$TENK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 25-NSE filed by TenX Keane Acquisition

SEC Form 10-Q filed by TenX Keane Acquisition

TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

SEC Form SC 13G filed by TenX Keane Acquisition

$TENK
Market Insights

Live Market Insights

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary With TenX Keane Acquisition For $10/Share